177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer

177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant... Eur J Nucl Med Mol Imaging (2017) 44:1663–1670 DOI 10.1007/s00259-017-3751-z ORIGINAL ARTICLE Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer 1 1 1 2 Axel Bräuer & Lena Sophie Grubert & Wolfgang Roll & Andres Jan Schrader & 1 2 1 Michael Schäfers & Martin Bögemann & Kambiz Rahbar Received: 12 May 2017 /Accepted: 1 June 2017 /Published online: 17 June 2017 Springer-Verlag GmbH Germany 2017 Abstract dose 6.11 GBq, IQR 5.9–6.3 GBq). The median follow-up Purpose Radioligand therapies targeting prostate-specific was 24 weeks (IQR 15–36 weeks). Follow-up data for at least membrane antigen (PSMA) have been established for the 12 weeks (PCWG3) were available in 76% (45) of the pa- treatment of metastasized castration-resistant prostate cancer tients. For outcome results data from all patients treated with (mCRPC) in the last decade and show promising response at least one cycle were analysed. A decline in prostate-specific rates and a favourable toxicity profile. The aim of this study antigen (PSA) of ≥50% occurred in 53%, and a decline in PSA was to evaluate the overall survival (OS) and to identify pa- of any amount in 91% of patients. The estimated median OS rameters predicting outcome in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Nuclear Medicine and Molecular Imaging Springer Journals

177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer

Loading next page...
 
/lp/springer_journal/177lu-psma-617-radioligand-therapy-and-outcome-in-patients-with-ajdpvsi471
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1619-7070
eISSN
1619-7089
D.O.I.
10.1007/s00259-017-3751-z
Publisher site
See Article on Publisher Site

Abstract

Eur J Nucl Med Mol Imaging (2017) 44:1663–1670 DOI 10.1007/s00259-017-3751-z ORIGINAL ARTICLE Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer 1 1 1 2 Axel Bräuer & Lena Sophie Grubert & Wolfgang Roll & Andres Jan Schrader & 1 2 1 Michael Schäfers & Martin Bögemann & Kambiz Rahbar Received: 12 May 2017 /Accepted: 1 June 2017 /Published online: 17 June 2017 Springer-Verlag GmbH Germany 2017 Abstract dose 6.11 GBq, IQR 5.9–6.3 GBq). The median follow-up Purpose Radioligand therapies targeting prostate-specific was 24 weeks (IQR 15–36 weeks). Follow-up data for at least membrane antigen (PSMA) have been established for the 12 weeks (PCWG3) were available in 76% (45) of the pa- treatment of metastasized castration-resistant prostate cancer tients. For outcome results data from all patients treated with (mCRPC) in the last decade and show promising response at least one cycle were analysed. A decline in prostate-specific rates and a favourable toxicity profile. The aim of this study antigen (PSA) of ≥50% occurred in 53%, and a decline in PSA was to evaluate the overall survival (OS) and to identify pa- of any amount in 91% of patients. The estimated median OS rameters predicting outcome in

Journal

European Journal of Nuclear Medicine and Molecular ImagingSpringer Journals

Published: Jun 17, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off